Results 1 to 10 of about 1,272,565 (330)

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Journal of Clinical Oncology, 2022
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
N. Pemmaraju, K. Sweet, A. Stein, E. Wang, D. Rizzieri, S. Vasu, T. Rosenblat, C. Brooks, N. Habboubi, T. Mughal, H. Kantarjian, M. Konopleva, A. Lane   +12 more
semanticscholar   +1 more source

Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches [PDF]

BioMed Research International, 2016
The presence of acquired mutations within theJAK2,CALR,andMPLgenes in the majority of patients with myeloproliferative neoplasms (MPN) affords the opportunity to utilise these mutations as markers of minimal residual disease (MRD). Reduction of the mutated allele burden has been reported in response to a number of therapeutic modalities including ...
Karl Haslam, Stephen E. Langabeer
openaire   +4 more sources

RESIDUAL RADIOPAQUE BOLUS IN MANAGING INTRASPINAL NEOPLASMS [PDF]

American Journal of Roentgenology, 1966
Patients with intraspinal tumors often undergo myelographic examination. The subsequent course and response of such patients to radiation therapy can be documented expeditiously by leaving behind a bolus of the contrast agent at the time of the initial study. The technique is described in detail and illustrated with the report of a typical case.
Giulio J. D'angio, Charles F. Martin, Eugene Gedgaudas   +2 more
openaire   +3 more sources

Rare chondrosarcoma of the breast treated with quadrantectomy instead of mastectomy. A case report [PDF]

, 2014
Breast chondrosarcoma is a rare sarcoma that mainly occurs in females >50 years old. To the best of our knowledge, only 16 cases were reported in the literature prior to 2013 and all patients were surgically treated by mastectomy, with or without ...
Badyal, Baldini, Beltaos, Bhosale, DANIELA SOTTILE, De Padua, Demetri, Errarhay, Faraht, FILIPPO CUSTURERI, Gupta, Gupta, Gurleyik, Guymar, Kennedy, Lakshmikantha, Lewin, LUCA DEL VECCHIO, Mujtaba, PAOLO URCIUOLI, Pasta, Patterson, Pencavel, Rakha, Rao, Stojadinovic, Thilagavathi, VALERIO D’ORAZI, Vera-Sempere, Verfaillie, VITTORIO PASTA, Zelek   +31 more
core   +14 more sources

Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a ten-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm

Haematologica, 2020
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematopoietic neoplasm whose immunophenotype remains incompletely characterized, particularly with regards to its distinction from reactive plasmacytoid dendritic cells (PDC). This limitation
Wei Wang, Joseph D. Khoury, Roberto N Miranda, Jeffrey L. Jorgensen, Jie Xu, S. Loghavi, Shaoying Li, N. Pemmaraju, Than Nguyen, L. J. Medeiros, Sa A. Wang   +10 more
semanticscholar   +1 more source

Nevus sebaceus with syringocystadenoma papilliferum, prurigo nodularis, apocrine cystadenoma, basaloid follicular proliferation, and sebaceoma: case report and review of nevus sebaceus-associated conditions [PDF]

, 2020
Nevus sebaceus is a benign skin hamartoma of congenital onset that grows during puberty, and in adulthood can develop secondary benign and malignant neoplasms.
Basu, Pallavi, Calame, Antoanella, Cohen, Philip R, Erickson, Christof P   +3 more
core   +1 more source

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances

Cancer Management and Research, 2020
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR-ABL1 fusion gene generation as a consequence of the t(9;22)(q34;q11) rearrangement.
C. Cumbo, L. Anelli, G. Specchia, F. Albano   +3 more
semanticscholar   +1 more source

Minimal/Measurable Residual Disease Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

The Journal of Molecular Diagnostics, 2023
High-throughput sequencing of the T-cell receptor beta (TRB) and gamma (TRG) loci is increasingly utilized due to its high sensitivity, specificity, and versatility in the diagnosis of various T-cell malignancies. Application of these technologies for tracking disease burden can be valuable in detecting recurrence, determining response to therapy ...
Jack K. Tung, Diwash Jangam, Chandler C. Ho, Eula Fung, Michael S. Khodadoust, Youn H. Kim, James L. Zehnder, Henning Stehr, Bing M. Zhang   +8 more
openaire   +2 more sources

Neural Transformers for Intraductal Papillary Mucosal Neoplasms (IPMN) Classification in MRI images [PDF]

, 2022
Early detection of precancerous cysts or neoplasms, i.e., Intraductal Papillary Mucosal Neoplasms (IPMN), in pancreas is a challenging and complex task, and it may lead to a more favourable outcome. Once detected, grading IPMNs accurately is also necessary, since low-risk IPMNs can be under surveillance program, while high-risk IPMNs have to be ...
arxiv   +1 more source

Mathematical modelling, selection and hierarchical inference to determine the minimal dose in IFN$α$ therapy against Myeloproliferative Neoplasms [PDF]

Mathematical Medicine and Biology: A Journal of the IMA, Volume 41, Issue 2, June 2024, Pages 110-134, 2021
Myeloproliferative Neoplasms (MPN) are blood cancers that appear after acquiring a driver mutation in a hematopoietic stem cell. These hematological malignancies result in the overproduction of mature blood cells and, if not treated, induce a risk of cardiovascular events and thrombosis. Pegylated IFN$\alpha$ is commonly used to treat MPN, but no clear
arxiv   +1 more source